E74.05
Lysosome-associated membrane protein 2 [LAMP2] deficiency
Clinical Classification Guidelines
Inclusion Terms
- Danon disease
Code Also
- , if applicable, associated manifestations such as:
- dilated cardiomyopathy (I42.0)
- obstructive hypertrophic cardiomyopathy (I42.1)
Medical Intelligence & Overview
Lysosome-associated membrane protein 2 deficiency, known as Danon disease, is a rare genetic disorder that affects multiple parts of the body. It is caused by mutations in the LAMP2 gene, which leads to a shortage or malfunction of a protein essential for lysosome function. Lysosomes are cellular structures responsible for breaking down waste materials and recycling components within cells. When LAMP2 is deficient, waste accumulates in cells, resulting in various health issues. This condition primarily impacts the heart, muscles, and brain, often leading to progressive complications such as cardiomyopathy, muscle weakness, and learning difficulties.
Causes & Symptoms
Clinical Causes: Genetic mutations in the LAMP2 gene Inherited in an X-linked dominant pattern, meaning the gene defect is on the X chromosome and can affect both males and females, though typically more severe in males No known environmental or lifestyle factors are directly linked to the development of the disorder
Key Symptoms: Cardiomyopathy, often hypertrophic, leading to heart failure or arrhythmias Muscle weakness and delayed motor development Learning difficulties and intellectual disabilities, more common in males Enlargement of the heart (cardiac hypertrophy) Possible general fatigue and reduced exercise capacity Potential eye problems, such as retinal dystrophy
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of clinical evaluation, family history assessment, and specialized tests. Key diagnostic methods include: - Genetic testing to identify mutations in the LAMP2 gene - Cardiac imaging, such as echocardiography or MRI, to evaluate heart structure and function - Muscle biopsies, which may reveal abnormal lysosomes or accumulated waste materials in muscle tissue - Electrocardiograms (ECG) to detect cardiac electrical abnormalities - Neuropsychological assessment to assess learning and behavioral issues Imaging and laboratory analyses support the identification of characteristic features associated with Danon disease, leading to a definitive diagnosis.
Treatment Protocols: Currently, there is no cure for LAMP2 deficiency or Danon disease. Treatment focuses on managing symptoms and preventing complications, including: - Medications such as beta-blockers or angiotensin-converting enzyme (ACE) inhibitors to manage cardiomyopathy and heart failure - Regular cardiac monitoring and potential device implantation (like implantable defibrillators) to prevent sudden cardiac death - Supportive therapies for muscle weakness, including physical therapy - Educational interventions and special support for learning difficulties - Liver or other organ transplants may be considered in severe cases involving organ failure - Ongoing research aims to develop targeted therapies that can correct the underlying genetic defect
Clinical Advice & FAQs
Billing Guidance
Is E74.05 a billable ICD-10 code?
Yes, E74.05 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E74.05?
Clinical documentation must specify the nature of Lysosome-associated membrane protein 2 [LAMP2] deficiency and any associated comorbidities for accurate reporting.
Cite this Clinical Reference